Publicaciones en colaboración con investigadores/as de Hospital Universitario de Valme (32)

2024

  1. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

    American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654

  2. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

  3. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

  4. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management

    Journal of Clinical Medicine, Vol. 12, Núm. 13

  2. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  3. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  4. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2022

  1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  2. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  2. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

2019

  1. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64

  2. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

    Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672

  3. Effectiveness and safety of the switch from remicade® to CT-P13 in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 13, Núm. 11, pp. 1380-1386

  4. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 579-592

  5. Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn's disease: Analysis from the PRACTICROHN study

    Gastroenterology Report, Vol. 7, Núm. 3, pp. 168-175

2018

  1. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

    Gastroenterology, Vol. 155, Núm. 4, pp. 1120-1127.e4

2017

  1. Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial

    Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301